NCT05527457View on ClinicalTrials.gov

BAY2586116 Nasal Spray and OSA Severity

PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

December 20, 2022

Study Completion Date

December 20, 2022

Conditions

Sleep Apnea, Obstructive

Interventions

DRUG

BAY2586116

160 μg BAY2586116 nasal spray application

DRUG

Placebo

Placebo (saline) nasal spray application

Trial Locations (1)

5042

Flinders University, Bedford Park

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Flinders University

OTHER